The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
Adrian Minson(The University of Melbourne), Andrew Grigg(The Royal Melbourne Hospital), Shaun Fleming(Peter MacCallum Cancer Centre), Rosemary Harrup(University of Tasmania), Amy P. Holmes(Canberra Hospital), Sumita Ratnasingam(Monash Health), Kah Lok Chan, Rebecca Cleary(Princess Alexandra Hospital), Ben Costello(Baker Heart and Diabetes Institute), Asma Ashraf(Calvary Mater Newcastle Hospital), Kate Burbury(The University of Melbourne), Cecily Forsyth(Gosford Hospital), Jake Shortt(The University of Melbourne), Lucy C. Fox(Peter MacCallum Cancer Centre), Katherine D. Cummins(Parker Institute for Cancer Immunotherapy), Maciek Tatarczuch(Peter MacCallum Cancer Centre), Faye Putt(Austin Hospital), Wei-Hsun Hsu(Royal Prince Alfred Hospital), Anthony P. Schwarer(The Alfred Hospital), David T Yeung(Royal Adelaide Hospital), Andrew McQuillan(Hollywood Orthopaedic Group), Olga Motorna(The University of Melbourne)
Cited by 26
Related Papers
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
|New England Journal of Medicine|2018|429